JOP20170154B1 - تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة - Google Patents

تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة

Info

Publication number
JOP20170154B1
JOP20170154B1 JOP/2017/0154A JOP20170154A JOP20170154B1 JO P20170154 B1 JOP20170154 B1 JO P20170154B1 JO P20170154 A JOP20170154 A JO P20170154A JO P20170154 B1 JOP20170154 B1 JO P20170154B1
Authority
JO
Jordan
Prior art keywords
compositions
disorders
treatment
methods
various diseases
Prior art date
Application number
JOP/2017/0154A
Other languages
English (en)
Inventor
Jason Cummings W
A Demopulos Gregory
Dudler Thomas
Schwaeble Hans-Wilhelm
W Tjoelker Larry
L Wood Christie
Yabuki Munehisa
Original Assignee
Omeros Corp
Univ Leicester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corp, Univ Leicester filed Critical Omeros Corp
Publication of JOP20170154A1 publication Critical patent/JOP20170154A1/ar
Application granted granted Critical
Publication of JOP20170154B1 publication Critical patent/JOP20170154B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y25/00—Nanomagnetism, e.g. magnetoimpedance, anisotropic magnetoresistance, giant magnetoresistance or tunneling magnetoresistance
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01F—COMPOUNDS OF THE METALS BERYLLIUM, MAGNESIUM, ALUMINIUM, CALCIUM, STRONTIUM, BARIUM, RADIUM, THORIUM, OR OF THE RARE-EARTH METALS
    • C01F17/00—Compounds of rare earth metals
    • C01F17/20—Compounds containing only rare earth metals as the metal element
    • C01F17/206—Compounds containing only rare earth metals as the metal element oxide or hydroxide being the only anion
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
    • C09K11/08—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials
    • C09K11/77—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials containing rare earth metals
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
    • C09K11/08—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials
    • C09K11/77—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials containing rare earth metals
    • C09K11/7728—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials containing rare earth metals containing europium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01F—MAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
    • H01F1/00—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
    • H01F1/0036—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties showing low dimensional magnetism, i.e. spin rearrangements due to a restriction of dimensions, e.g. showing giant magnetoresistivity
    • H01F1/0045—Zero dimensional, e.g. nanoparticles, soft nanoparticles for medical/biological use
    • H01F1/0054—Coated nanoparticles, e.g. nanoparticles coated with organic surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2002/00—Crystal-structural characteristics
    • C01P2002/50—Solid solutions
    • C01P2002/52—Solid solutions containing elements as dopants
    • C01P2002/54—Solid solutions containing elements as dopants one element only
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2002/00—Crystal-structural characteristics
    • C01P2002/80—Crystal-structural characteristics defined by measured data other than those specified in group C01P2002/70
    • C01P2002/84—Crystal-structural characteristics defined by measured data other than those specified in group C01P2002/70 by UV- or VIS- data
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2004/00—Particle morphology
    • C01P2004/60—Particles characterised by their size
    • C01P2004/64—Nanometer sized, i.e. from 1-100 nanometer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

يتعلق الاختراع الحالي بأجسام مضادة وتركيبات مثبطة لـ MASP-3 تشتمل على مثل هذه الأجسام المضادة للاستخدام في تثبيط التأثيرات غير الملائمة لتنشيط المتمم المعتمد على MASP-3.
JOP/2017/0154A 2016-08-01 2017-07-03 تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة JOP20170154B1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662369674P 2016-08-01 2016-08-01
US201662419420P 2016-11-08 2016-11-08
US201762478336P 2017-03-29 2017-03-29

Publications (2)

Publication Number Publication Date
JOP20170154A1 JOP20170154A1 (ar) 2019-01-30
JOP20170154B1 true JOP20170154B1 (ar) 2023-03-28

Family

ID=61073545

Family Applications (6)

Application Number Title Priority Date Filing Date
JOP/2017/0154A JOP20170154B1 (ar) 2016-08-01 2017-07-03 تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
JOP/2022/0243A JOP20220243A1 (ar) 2016-08-01 2022-10-03 أجسام مضادة ترتبط تحديداً بـ masp-3 لعلاج أمراض واضطرابات متنوعة
JOP/2022/0241A JOP20220241A1 (ar) 2016-08-01 2022-10-03 أحماض نووية تشفر أجسام مضادة ترتبط تحديدا بـ masp-3
JOP/2022/0242A JOP20220242A1 (ar) 2016-08-01 2022-10-03 أحماض نووية تشفر أجسام مضادة ترتبط تحديدا بـ masp-3
JOP/2022/0245A JOP20220245A1 (ar) 2016-08-01 2022-10-03 أجسام مضادة ترتبط تحديداً بـ masp-3 لعلاج أمراض واضطرابات متنوعة
JOP/2022/0244A JOP20220244A1 (ar) 2016-08-01 2022-10-03 أجسام مضادة ترتبط تحديداً بـ masp-3 لعلاج أمراض واضطرابات متنوعة

Family Applications After (5)

Application Number Title Priority Date Filing Date
JOP/2022/0243A JOP20220243A1 (ar) 2016-08-01 2022-10-03 أجسام مضادة ترتبط تحديداً بـ masp-3 لعلاج أمراض واضطرابات متنوعة
JOP/2022/0241A JOP20220241A1 (ar) 2016-08-01 2022-10-03 أحماض نووية تشفر أجسام مضادة ترتبط تحديدا بـ masp-3
JOP/2022/0242A JOP20220242A1 (ar) 2016-08-01 2022-10-03 أحماض نووية تشفر أجسام مضادة ترتبط تحديدا بـ masp-3
JOP/2022/0245A JOP20220245A1 (ar) 2016-08-01 2022-10-03 أجسام مضادة ترتبط تحديداً بـ masp-3 لعلاج أمراض واضطرابات متنوعة
JOP/2022/0244A JOP20220244A1 (ar) 2016-08-01 2022-10-03 أجسام مضادة ترتبط تحديداً بـ masp-3 لعلاج أمراض واضطرابات متنوعة

Country Status (25)

Country Link
US (4) US10639369B2 (ar)
EP (1) EP3490603A4 (ar)
JP (3) JP6971306B2 (ar)
KR (3) KR102382804B1 (ar)
CN (4) CN116333147A (ar)
AU (4) AU2017306069B2 (ar)
BR (1) BR112019001247A2 (ar)
CA (3) CA3122348A1 (ar)
CL (1) CL2019000230A1 (ar)
CO (1) CO2019001212A2 (ar)
CR (1) CR20190105A (ar)
CU (1) CU24568B1 (ar)
EC (1) ECSP19015192A (ar)
GE (1) GEP20247593B (ar)
IL (3) IL298689B2 (ar)
JO (6) JOP20170154B1 (ar)
MA (1) MA45798A (ar)
MX (3) MX2019000965A (ar)
PE (1) PE20190389A1 (ar)
PH (1) PH12019500204A1 (ar)
SA (1) SA519400950B1 (ar)
SG (3) SG10202010277SA (ar)
TW (4) TW202334243A (ar)
UY (1) UY37349A (ar)
WO (1) WO2018026722A1 (ar)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
IL303696A (en) 2017-03-01 2023-08-01 Achillion Pharmaceuticals Inc Aryl, heteroaryl and heterocyclic pharmaceutical compounds for the treatment of medical disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
JP2021525860A (ja) * 2018-05-25 2021-09-27 アキリオン ファーマシューティカルズ，インコーポレーテッド 補体代替経路関連腎症バイオマーカー
WO2020051538A1 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
US11814391B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
KR20210093855A (ko) 2018-09-25 2021-07-28 아칠리온 파르마세우티칼스 인코포레이티드 보체 인자 d 억제제의 형태체 형태
CN110244053B (zh) * 2019-05-09 2022-03-11 北京大学第三医院（北京大学第三临床医学院） 用于诊断狼疮肾炎并肺动脉高压疾病的分子标志物及其用途
CN112812182B (zh) * 2019-11-15 2023-01-06 深圳宾德生物技术有限公司 一种靶向fgfr4的单链抗体、嵌合抗原受体、嵌合抗原受体t细胞及其制备方法和应用
WO2021147954A1 (zh) * 2020-01-21 2021-07-29 上海柏全生物科技有限公司 Semg2抗体及其用途
MX2023001937A (es) * 2020-08-18 2023-04-05 Omeros Corp Anticuerpos monoclonales, composiciones y métodos para detectar el factor d del complemento.
CN112950324B (zh) * 2021-03-15 2022-06-03 重庆邮电大学 一种知识图谱辅助的成对排序个性化电商推荐方法及系统
CN115304670A (zh) * 2021-05-07 2022-11-08 华南农业大学 一种猫冠状病毒核衣壳蛋白的鼠源单克隆抗体及其编码基因和应用
US20230416406A1 (en) * 2022-03-10 2023-12-28 Omeros Corporation Masp-2 and masp-3 inhibitors, and related compositions and methods, for treatment of sickle cell disease
WO2024097163A1 (en) * 2022-11-02 2024-05-10 Omeros Corporation Therapeutic methods and uses for antibodies to human masp-3

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
AU690528B2 (en) 1992-12-04 1998-04-30 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5856121A (en) 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US7273925B1 (en) 1998-12-15 2007-09-25 Brigham And Women's Hospital, Inc. Methods and products for regulating lectin complement pathway associated complement activation
US20040031072A1 (en) * 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
CN1433466A (zh) * 1999-12-02 2003-07-30 詹斯·C·詹斯尼厄斯 Masp－3,一种固定补体的酶,及其应用
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
CN100519643C (zh) 2002-07-19 2009-07-29 奥默罗斯公司 可生物降解的三嵌段共聚物,它们的合成方法和从它制得的水凝胶和生物材料
JP4601426B2 (ja) 2002-09-06 2010-12-22 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体成分ｃ５に対する抗体を使用する喘息の処置の方法
WO2004075837A2 (en) 2003-02-21 2004-09-10 Tanox, Inc. Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
DE102004017370A1 (de) 2004-04-08 2005-10-27 Nutrinova Nutrition Specialties & Food Ingredients Gmbh PUFA-PKS Gene aus Ulkenia
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AU2006283532B2 (en) 2005-08-19 2012-04-26 Abbvie Inc. Dual variable domain immunoglobin and uses thereof
CA2685714C (en) 2007-05-31 2016-04-12 University Of Washington Inducible mutagenesis of target genes
KR102184713B1 (ko) 2009-07-17 2020-12-01 오메로스 코포레이션 보체 활성화의 억제제로서의 masp 이소형
CN102574915B (zh) * 2009-08-06 2014-10-22 伊缪纳斯制药株式会社 特异性结合Aβ寡聚体的抗体及其用途
WO2011026242A1 (en) * 2009-09-03 2011-03-10 Vancouver Biotech Ltd. Monoclonal antibodies against gonadotropin-releasing hormone receptor
CA2789071C (en) * 2010-03-05 2018-03-27 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
US20120122107A1 (en) 2010-11-16 2012-05-17 Aarhus Universitet Homeostatic multidomain protein, and uses for it
CA3131223C (en) * 2011-05-04 2024-01-30 Omeros Corporation Compositions for inhibiting masp-2 dependent complement activation
SI2833907T1 (en) * 2012-04-06 2018-07-31 Omeros Corporation COMPOSITION AND METHODS OF INJECTION OF MASP-1 AND / OR MASP-3 FOR TREATMENT OF PAROXYSIMAL NIGHT CHEMOGLOBINURIA
AU2013277309B2 (en) * 2012-06-18 2018-03-29 Omeros Corporation Compositions and methods of inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the treatment of various diseases and disorders
ES2760023T3 (es) * 2013-02-20 2020-05-12 Univ Pennsylvania Tratamiento del cáncer utilizando receptor de antígeno quimérico anti-EGFRvIII humanizado
CA2902026C (en) * 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
US10059775B2 (en) * 2014-01-29 2018-08-28 Dana-Farber Cancer Institute, Inc. Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)

Also Published As

Publication number Publication date
US20180140697A1 (en) 2018-05-24
CR20190105A (es) 2019-05-14
CA3122348A1 (en) 2018-02-08
KR102553777B1 (ko) 2023-07-11
KR20220045078A (ko) 2022-04-12
SA519400950B1 (ar) 2022-03-16
PE20190389A1 (es) 2019-03-13
IL298690B2 (en) 2023-10-01
TW202334243A (zh) 2023-09-01
JOP20220245A1 (ar) 2023-01-30
EP3490603A4 (en) 2020-11-04
US20210275667A1 (en) 2021-09-09
JOP20220243A1 (ar) 2023-01-30
US11027015B2 (en) 2021-06-08
IL264592B1 (en) 2023-06-01
KR102382804B1 (ko) 2022-04-11
SG11201900606VA (en) 2019-02-27
TW201805304A (zh) 2018-02-16
CL2019000230A1 (es) 2019-07-12
PH12019500204A1 (en) 2020-01-20
JP7350821B2 (ja) 2023-09-26
TW202214689A (zh) 2022-04-16
UY37349A (es) 2018-02-28
KR102624948B1 (ko) 2024-01-17
ECSP19015192A (es) 2019-03-29
AU2022256090A1 (en) 2022-11-24
US10639369B2 (en) 2020-05-05
EP3490603A1 (en) 2019-06-05
KR20220046002A (ko) 2022-04-13
SG10202010279YA (en) 2020-11-27
JP7350822B2 (ja) 2023-09-26
MX2019000965A (es) 2019-08-29
US10745274B1 (en) 2020-08-18
JP2022033733A (ja) 2022-03-02
AU2017306069B2 (en) 2020-09-03
WO2018026722A8 (en) 2018-12-27
JP2019533982A (ja) 2019-11-28
US20200317510A1 (en) 2020-10-08
CU24568B1 (es) 2022-01-13
CN109715209B (zh) 2022-12-06
JOP20220244A1 (ar) 2023-01-30
MX2023000525A (es) 2023-03-06
MA45798A (fr) 2019-06-05
TWI820555B (zh) 2023-11-01
IL298689B2 (en) 2023-10-01
JP6971306B2 (ja) 2021-11-24
AU2020250188B2 (en) 2023-03-09
CN116333146A (zh) 2023-06-27
IL298689A (en) 2023-01-01
JOP20220241A1 (ar) 2023-01-30
JOP20220242A1 (ar) 2023-01-30
CN116327918A (zh) 2023-06-27
IL264592B2 (en) 2023-10-01
IL298690B1 (en) 2023-06-01
SG10202010277SA (en) 2020-11-27
JOP20170154A1 (ar) 2019-01-30
US20200270125A1 (en) 2020-08-27
JP2022033732A (ja) 2022-03-02
BR112019001247A2 (pt) 2019-06-25
CN116333147A (zh) 2023-06-27
IL298690A (en) 2023-01-01
NZ751019A (en) 2021-10-29
CO2019001212A2 (es) 2019-02-19
TWI756248B (zh) 2022-03-01
AU2017306069A1 (en) 2019-01-03
US11883493B2 (en) 2024-01-30
CA3031980A1 (en) 2018-02-08
CA3173979A1 (en) 2018-02-08
IL264592A (en) 2019-02-28
KR20190035796A (ko) 2019-04-03
AU2020250188A1 (en) 2020-11-05
AU2020204551A1 (en) 2020-07-30
MX2023000482A (es) 2023-02-13
IL298689B1 (en) 2023-06-01
GEP20247593B (en) 2024-02-12
AU2020204551B2 (en) 2022-09-15
CN109715209A (zh) 2019-05-03
CU20190006A7 (es) 2019-09-04
WO2018026722A1 (en) 2018-02-08
TW202214690A (zh) 2022-04-16
CA3031980C (en) 2022-12-06

Similar Documents

Publication Publication Date Title
PH12019500204A1 (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
ZA201801852B (en) Anti¿pd¿1 antibodies and compositions
PH12018500086A1 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
PH12019500494A1 (en) Formulations of (r)-2-amino-3-phenylpropyl carbamate
MX2020001774A (es) Composiciones y métodos para tratar enfermedad colestásica.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
EA201891468A1 (ru) Композиции и способы для снижения экспрессии tau
MX2018012902A (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
GEP201706795B (en) Hexahydrofuropyrroles as pde1 inhibitors
PH12017501694A1 (en) Compositions for the treatment of fibrosis and fibrosis-related diseases
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
PH12017501693A1 (en) Compositions for the treatment of kidney and/or liver diseases
EA201990393A1 (ru) Композиции и способы для ингибирования masp-3, применяемые в целях лечения различных заболеваний и расстройств
MX2016010967A (es) Nuevas composiciones para tratar lesiones neuronales mecanicas.
MX2017014893A (es) Composicion herbal para el tratamiento del dolor de espalda.